ROSCO: For Investigators

B

Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo-adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy.

Recruitment

  • Date First Patient Randomised: 26-Nov-2015
  • Recruitment total as of 31-May-2023: 990

Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the ROSCO Trial Office.

Trial Documents

A link to the current trial protocol is provided below. If there has been a recent amendment to the trial please ensure you have R&D approval for this specific version of the protocol before using as a reference.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc.) can be requested by contacting the team at the ROSCO Trial Office.

Newsletters 

Contact Details

Chief Investigator
Professor Daniel Rea
Cancer Research UK Clinical Trials Unit (CRCTU), University of
Birmingham, Birmingham. B15 2TT
Tel: +44 (0) 121 371 5124

ROSCO Trial Office
Trial Coordinator:                                Natalia Nicholson 
Data Manager:                                      Amy Hail
Trial Monitor:                                        Davina Scott 

Trial Management Team Leader:        Claire Gaunt
Senior Trial Coordinator:                     Liz Southgate 
Trial Statistician:                                   Sarah Pirrie

Cancer Research UK Clinical Trials Unit (CRCTU)
Department of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Enquiries
Telephone: +44 (0) 121 414 3797
Email: rosco@trials.bham.ac.uk

Serious Adverse Event Reporting
Email: reg@trials.bham.ac.uk

Sponsor
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Publications

Abstracts
Rea D et al. (2015) ROSCO A randomised phase III, stratified CEP17/TOPOIIA biomarker trial of neo-adjuvant 5-Flourouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy. San Antonio Breast Cancer Symposium. Abstract No.: OT3-02-02. 

Papers
There have been no papers published for this trial to date.